Brief: Bubs Australia Says FDA Continues Review Of Bubs' Infant Formula Submissions
29/12/2025 01:09
Dec 29 (Reuters) - Bubs Australia Ltd BUB.AX: FDA CONTINUES REVIEW OF BUBS' INFANT FORMULA SUBMISSIONS CONFIRMS THAT IT IS ON TRACK TO RECEIVE FDA APPROVAL FDA CONFIRMED IT WILL CONTINUE TO FACILITATE IMPORTATION, OTHERS OF BUBS' INFANT FORMULA PRODUCTS IN US AFTER 31 DEC 2025 Further company coverage: BUB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bubs Australia
See all newsBubs Australia hits near two-month low as quarterly revenue declines
Bubs Australia shares set for 15% weekly gain on FDA approval for infant formula products
Bubs Australia extends rally after infant formulas get US FDA approval
Bubs Australia gets permanent FDA nod for infant formula sales in US, shares jump (updated)
Bubs Australia secures permanent FDA nod for infant formula sales in US, shares jump